Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
AIFAM Group LLC, founded in 2001, is an alternative investment management firm with offices in New York and Tokyo. The firm specializes in managing custom portfolios for top-tier Japanese institutions, focusing on hedge funds, private equity, venture capital, and private credit. AIFAM serves as the lead manager for clients' alternative investments and operates the Triple Bridge Acceleration Program (TBAP), which is dedicated to fostering innovation in the medical and life sciences sectors in Japan.
Since its inception, AIFAM has managed over 300 investments and 40 secondary deals. The firm is recognized as a qualified venture capital entity by the Japan Agency for Medical Research and Development (AMED), which underscores its commitment to supporting the pharmaceutical startup ecosystem. AIFAM's dual presence in New York and Tokyo allows it to facilitate cross-border investments, connecting Japanese capital with global opportunities.
AIFAM Group LLC invests across a wide range of alternative investment strategies, including hedge funds, private equity, venture capital, and private credit. The firm focuses on various stages of investment, from Friends & Family and Angel rounds to Series A through Series F, as well as Growth Equity, Pre-IPO, and Secondary deals. AIFAM's geographic focus spans North America and Asia, with a particular emphasis on the healthcare, biotech, fintech, AI, and climate sectors.
The firm aims to connect Japanese institutional investors with global opportunities, particularly in healthcare innovation. AIFAM's investment strategy is characterized by its extensive networks and tailored investment management services, which are designed to meet the specific needs of its clients. The firm looks for founders who demonstrate strong leadership, innovative ideas, and a clear vision for their companies.
AIFAM Group LLC has managed over 300 investments since its founding, including 40 secondary deals. While specific portfolio companies were not detailed in the provided content, the firm is known for its focus on sectors such as healthcare, biotech, fintech, AI, and climate. This diverse portfolio reflects AIFAM's commitment to investing in innovative companies that align with its investment thesis.
The firm operates the Triple Bridge Acceleration Program (TBAP), which is dedicated to fostering innovation in the medical and life sciences sectors in Japan. This program enhances AIFAM's ability to support startups in these critical areas, although specific outcomes or notable exits from the portfolio were not disclosed.
Takuma Aoyama - CIO, CEO. Aoyama has a background in asset management with experience at UBS Global Asset Management and Long-Term Credit Bank of Japan. He has also served as a corporate VC at Astellas Venture Management.
Sanjay Mitta - Portfolio Manager. Mitta brings expertise in managing investment portfolios and has a strong background in alternative investments.
Gregory Scimeca - Senior Analyst. Scimeca specializes in market analysis and investment research, contributing to AIFAM's strategic decision-making.
David Lane - Senior Analyst. Lane focuses on investment evaluation and portfolio management, leveraging his analytical skills to support AIFAM's investment strategies.
Chris D. Mroz, CFA - Senior Analyst. Mroz has a strong background in finance and investment analysis, providing insights that guide AIFAM's investment decisions.
Go Sato - Executive Director. Sato oversees operations and strategic initiatives within AIFAM, ensuring alignment with the firm's investment goals.
Michael Hanisch - Director of Operations. Hanisch manages operational aspects of AIFAM's investment processes, enhancing efficiency and effectiveness.
Yuki Misaki - Director of Operations. Misaki supports AIFAM's operational strategies, contributing to the firm's overall success.
To pitch AIFAM Group LLC, startups should use the preferred channel of their website at triplebridge.net or email general@aifaminc.com. The pitch deck should include essential elements such as the business model, market analysis, team background, and financial projections. AIFAM values thorough and well-prepared presentations that clearly articulate the startup's vision and potential.
Response times may vary, but founders should expect a thorough review process. A warm introduction can enhance the chances of a successful pitch, as AIFAM values connections within its network.
AIFAM operates the Triple Bridge Acceleration Program (TBAP), which is dedicated to fostering innovation in the medical and life sciences sectors in Japan. This program aims to connect startups with resources and expertise to accelerate their growth and development.
Details regarding the duration, cohort size, investment amount, or application deadlines for TBAP were not provided, but the program is designed to support startups in navigating the complexities of the healthcare market.
AIFAM Group LLC has been active in managing custom discretionary portfolios for top-tier Japanese institutions. The firm operates the Triple Bridge Acceleration Program (TBAP), which focuses on fostering innovation in the medical and life sciences sectors in Japan. AIFAM is recognized as a qualified venture capital entity by the Japan Agency for Medical Research and Development (AMED), highlighting its commitment to supporting the pharmaceutical startup ecosystem.
Recent activities include managing over 300 investments and 40 secondary deals since its inception. The firm continues to seek opportunities that align with its investment thesis, particularly in healthcare innovation.
What are AIFAM's investment criteria?
AIFAM Group LLC invests in various stages, including Friends & Family, Angel, Pre-seed, Seed, Series A through Series F, and Growth Equity. The firm focuses on sectors such as healthcare, biotech, fintech, AI, and climate.
How can startups apply or pitch to AIFAM?
What makes AIFAM different from other venture capital firms?
AIFAM connects Japanese institutional investors with global alternative investments, particularly in healthcare innovation. The firm leverages its extensive networks and expertise in alternative investments to provide strategic guidance and access to institutional capital.
What is AIFAM's geographic scope?
AIFAM operates primarily in North America and Asia, with a strong focus on connecting Japanese capital with global opportunities.
What is AIFAM's post-investment involvement like?
AIFAM adds value to its portfolio companies through strategic guidance, operational support, and access to institutional capital. The firm actively engages with its portfolio companies to help them achieve their growth objectives.
What is the typical check size for AIFAM's investments?
While specific check sizes are not disclosed, AIFAM invests across a range of stages, indicating flexibility in its investment amounts based on the needs of the startup and the stage of development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.